Assignee
FORTY SEVEN INC
US·11 granted patents·10 pending applications·15 citations·filing 2017–2024
Top patents by PatentIndex Score
21 records- 0192US11208482B2Humanized antibodies against c-KitFORTY SEVEN INC·Filed 2019·Granted Dec 28, 2021·8 cites·10 claims
- 0290US11041022B2Humanized antibodies against c-KitFORTY SEVEN INC·Filed 2020·Granted Jun 22, 2021·2 cites·16 claims
- 0381US11643461B2Humanized, mouse or chimeric anti-CD47 monoclonal antibodiesFORTY SEVEN INC·Filed 2020·Granted May 9, 2023·1 cites·24 claims
- 0481US2025034246A1Humanized antibodies against c-kitFORTY SEVEN INC·Filed 2024·Application pending·0 cites
- 0579US10961318B2Anti-SIRP-α antibodies and related methodsFORTY SEVEN INC·Filed 2018·Granted Mar 30, 2021·1 cites·33 claims
- 0678US10927173B2Humanized, mouse or chimeric anti-CD47 monoclonal antibodiesFORTY SEVEN INC·Filed 2017·Granted Feb 23, 2021·2 cites·21 claims
- 0777US11891450B2Anti-CD47 agent-based treatment of CD20-positive cancerFORTY SEVEN INC·Filed 2019·Granted Feb 6, 2024·1 cites·20 claims
- 0875US12091458B2Humanized antibodies against c-KitFORTY SEVEN INC·Filed 2021·Granted Sep 17, 2024·0 cites·14 claims
- 0973US2024218077A1Anti-cd47 agent-based treatment of cd20-positive cancerFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 1072US2024150461A1Anti-cd47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 1169US12060423B2Humanized, mouse or chimeric anti-CD47 monoclonal antibodiesFORTY SEVEN INC·Filed 2022·Granted Aug 13, 2024·0 cites·19 claims
- 1268US11753480B2Anti-SIRP-alpha antibodies and related methodsFORTY SEVEN INC·Filed 2021·Granted Sep 12, 2023·0 cites·23 claims
- 1367US2024124578A1Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemiaFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 1462US11802153B2Anti-CD47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2018·Granted Oct 31, 2023·0 cites·17 claims
- 1560US11795223B2Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemiaFORTY SEVEN INC·Filed 2020·Granted Oct 24, 2023·0 cites·12 claims
- 1651US2022185905A1Multispecific agents for treatment of cancerFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 1750US2021147568A1Anti-cd47 based treatment of blood cancerFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 1849US2020369767A1Regimes for co-administration of immunotherapeutic agents against c-kit and cd47FORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 1947US2022288118A1Depletion regimes for engineered t-cell or nk-cell therapyFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 2047US2022023348A1Genetically modified hspcs resistant to ablation regimeFORTY SEVEN INC·Filed 2019·Application pending·0 cites
- 2144US2021047416A1Treatment of ovarian cancer with anti-cd47 and anti-pd-l1FORTY SEVEN INC·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →